T-DM1 is at present the only approved ADC for treatment of advanced HER2-positive breast cancer, based on the phase 3 registration trials EMILIA [17] and THERESA [18] comparing T-DM1 with capecitabine plus lapatinib and treatment of physicians choice, respectively. The gene discussed is ERBB2; the disease is breast cancer.